-
Over the last five years, there has been an increased emphasis on screening for aneuploidy, in part due to the ACOG endorsement of the concept of offering nuchal translucency (NT) and biochemical screening to all pregnant patients, and not just those of advanced maternal age (AMA).
-
It is unclear how many practitioners around the world use routine episiotomy today as a way to avoid third and fourth degree lacerations. There certainly was a period of time when episiotomy was a routine practice in nulliparas.
-
The primary purpose of this phase III study was to determine if maintenance of hemoglobin values above 12 g/dL by use of R-HUEPO during chemoradiotherapy (weekly cisplatin) for advanced cervix cancer was associated with improved outcomes (progression-free and overall survival and local control rates) relative to maintenance of hemoglobin values above 10 g/dL by way of non-R-HUEPO methods.
-
Sentinel node localization and sampling has become a standard practice in the evaluation of regional nodal status for patients with breast cancer and cutaneous melanoma.
-
The principal purpose of this clinical study was to evaluate the efficacy of gemcitabine relative to a clinical standard therapy, pegylated liposomal doxorubicin (PLD) in women with ovarian cancer relapsing within a year of primary treatments.
-
-
In a previous Clinical Alert, the risk of uterine rupture in patients attempting vaginal birth after cesarean sections (VBACs) was addressed when it appeared that there was a distinct downturn in the amount of VBACs being done in the USA.
-
One hundred and twenty subjects with symptoms of idiopathic detrusor overactivity (OAB) were recruited to evaluate the efficacy of reflexology compared to nonspecific foot massage.
-
In this issue: Does erythropoietin worsen cancer death rates? Most hypothyroid patients can be replaced with levothyroxine alone without additional T3. Does aggressive control in type 2 diabetes save lives?
-
The Women's Health Initiative investigators reported health outcomes at 3 years after the estrogen-progestin arm of the clinical trial was canceled.